Group 1 - The company reported a total operating revenue of 130 million yuan for the first half of 2025, representing a year-on-year increase of 61.8%. However, the total profit reached -171 million yuan, with a net profit attributable to shareholders of -162 million yuan [1] - The company is actively promoting the launch of APL-1702 in China, with the application for listing accepted by the National Medical Products Administration in May 2024. The company has prioritized the review and approval process for this product [1] - APL-1702's international multi-center Phase III clinical trial results were selected for presentation at the 2025 International Photodynamic Association conference. The company has also received feedback from the FDA regarding the design of a Phase III clinical trial for APL-1702 in the U.S. [1] Group 2 - The company has achieved continuous sales growth through both self-operated and commissioned sales models, successfully reaching target cities and hospitals. The company has maintained its sales revenue targets and rapidly increased market penetration despite intense competition [1] - The company is focusing on deepening its product pipeline around urogenital system diseases through independent research and strategic partnerships. Revenue projections for 2025-2027 are estimated at 361 million yuan, 650 million yuan, and 940 million yuan respectively [2]